Literature DB >> 19158483

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.

Ayesha B Alvero1, Rui Chen, Han-Hsuan Fu, Michele Montagna, Peter E Schwartz, Thomas Rutherford, Dan-Arin Silasi, Karina D Steffensen, Marianne Waldstrom, Irene Visintin, Gil Mor.   

Abstract

A major burden in the treatment of ovarian cancer is the high percentage of recurrence and chemoresistance. Cancer stem cells (CSCs) provide a reservoir of cells that can self-renew, can maintain the tumor by generating differentiated cells [non-stem cells (non-CSCs)] which make up the bulk of the tumor and may be the primary source of recurrence. We describe the characterization of human ovarian cancer stem cells (OCSCs). These cells have a distinctive genetic profile that confers them with the capacity to recapitulate the original tumor, proliferate with chemotherapy, and promote recurrence. CSC identified in EOC cells isolated form ascites and solid tumors are characterized by: CD44+, MyD88+, constitutive NFkappaB activity and cytokine and chemokine production, high capacity for repair, chemoresistance to conventional chemotherapies, resistance to TNFalpha-mediated apoptosis, capacity to form spheroids in suspension, and the ability to recapitulate in vivo the original tumor. Chemotherapy eliminates the bulk of the tumor but it leaves a core of cancer cells with high capacity for repair and renewal. The molecular properties identified in these cells may explain some of the unique characteristics of CSCs that control self-renewal and drive metastasis. The identification and cloning of human OCSCs can aid in the development of better therapeutic approaches for ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158483      PMCID: PMC3041590          DOI: 10.4161/cc.8.1.7533

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

Review 1.  Prostate cancer stem cells.

Authors:  Anne T Collins; Norman J Maitland
Journal:  Eur J Cancer       Date:  2006-05-02       Impact factor: 9.162

2.  Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner.

Authors:  Chung-Hang Leung; Susan P Grill; Wing Lam; Wenli Gao; Han-Dong Sun; Yung-Chi Cheng
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

3.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 4.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.

Authors:  Sharmila A Bapat; Avinash M Mali; Chaitanyananda B Koppikar; Nawneet K Kurrey
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

6.  Stem cells and cancer: two faces of eve.

Authors:  Michael F Clarke; Margaret Fuller
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

Review 7.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

8.  Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis.

Authors:  Masayuki Fukata; Kathrin S Michelsen; Rajaraman Eri; Lisa S Thomas; Bing Hu; Katie Lukasek; Cynthia C Nast; Juan Lechago; Ruliang Xu; Yoshikazu Naiki; Antoine Soliman; Moshe Arditi; Maria T Abreu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-05       Impact factor: 4.052

9.  A tumorigenic subpopulation with stem cell properties in melanomas.

Authors:  Dong Fang; Thiennga K Nguyen; Kim Leishear; Rena Finko; Angela N Kulp; Susan Hotz; Patricia A Van Belle; Xiaowei Xu; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

10.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.

Authors:  Michael G Kelly; Ayesha B Alvero; Rui Chen; Dan-Arin Silasi; Vikki M Abrahams; Serena Chan; Irene Visintin; Thomas Rutherford; Gil Mor
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

View more
  234 in total

1.  Isolation and characterization of stem-like cells from a human ovarian cancer cell line.

Authors:  Lijuan Wang; Roman Mezencev; Nathan J Bowen; Lilya V Matyunina; John F McDonald
Journal:  Mol Cell Biochem       Date:  2011-12-09       Impact factor: 3.396

2.  Detection of single enzymatic events in rare or single cells using microfluidics.

Authors:  Sissel Juul; Yi-Ping Ho; Jørn Koch; Felicie F Andersen; Magnus Stougaard; Kam W Leong; Birgitta R Knudsen
Journal:  ACS Nano       Date:  2011-09-28       Impact factor: 15.881

3.  An in vitro model for the study of human implantation.

Authors:  Jennie C Holmberg; Severina Haddad; Vera Wünsche; Yang Yang; Paulomi B Aldo; Yulia Gnainsky; Irit Granot; Nava Dekel; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-12-12       Impact factor: 3.886

4.  Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors.

Authors:  John Pizzonia; Jennie Holmberg; Sean Orton; Ayesha Alvero; Oscar Viteri; William McLaughlin; Gil Feke; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-09-28       Impact factor: 3.886

Review 5.  Involvement of non-vascular stem cells in blood vessel formation.

Authors:  Nobuyuki Takakura
Journal:  Int J Hematol       Date:  2012-02-04       Impact factor: 2.490

6.  Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Authors:  Rohann J M Correa; Monica Komar; Jessica G K Tong; Milani Sivapragasam; Masmudur M Rahman; Grant McFadden; Gabriel E Dimattia; Trevor G Shepherd
Journal:  Gynecol Oncol       Date:  2012-02-01       Impact factor: 5.482

Review 7.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

8.  Development of enantioselective synthetic routes to (-)-kinamycin F and (-)-lomaiviticin aglycon.

Authors:  Christina M Woo; Shivajirao L Gholap; Liang Lu; Miho Kaneko; Zhenwu Li; P C Ravikumar; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2012-10-03       Impact factor: 15.419

9.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Authors:  Ilana Chefetz; Ayesha B Alvero; Jennie C Holmberg; Noah Lebowitz; Vinicius Craveiro; Yang Yang-Hartwich; Gang Yin; Lisa Squillace; Marta Gurrea Soteras; Paulomi Aldo; Gil Mor
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

10.  DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Authors:  Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal
Journal:  J Cancer Stem Cell Res       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.